Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two-Drug cocktail targets Hard-to-Treat cancer mutation

NCT ID NCT05379946

Ongoing Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced or metastatic solid tumors that have a specific genetic change called KRasG12C. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. Participants must have tumors that have not responded to or are not eligible for standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of two oral drugs: D-1553, which targets the KRasG12C mutation, and IN10018
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have a KRasG12C mutation and have not responded to other therapies.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so the safety and effectiveness of the combination are not yet proven. It may not work for all tumor types or may cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

  • Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,

    Hangzhou, Zhejiang, 310005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.